Congruence Therapeutics Announces Oral Presentation on Novel GCase Activators and Correctors for Parkinson’s Disease with GBA1 Mutations at the GBA1 Meeting 2025

/PRNewswire/ — Congruence Therapeutics, a computationally-driven biotechnology company building a unique pipeline of correctors for diseases of protein…
June 2, 2025